NRXP · NRX Pharmaceuticals Inc
United States · RS rating 25 · As of 2026-11-03
| Price | 2.24 USD |
|---|---|
| 1-day change | +3.2% |
| RS rating (overall / 1M / 3M / 12M) | 25 / 20 / 24 / 32 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 36 / 25 / 34 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | +306.2% |
| Distance from 52-week high | +51.5% |
| Market cap (USD) | $93.9M |